Game night at the Garden.

Boston Celtics vs Charlotte

Last game for us in the regular season. On to the playoffs.

#differenthere

So proud of Baim Institute ‘s Harriette Van Spall Harriette Van Spall, MD MPH as co- chair of these new guidelines about driver safety onlinecjc.ca/pb-assets/Heal…

Late breaking clinical trials Deep Dive starting now in Ballroom 4! Much more exciting than the solar eclipse! #ACC24 ⁦Athena Poppas, MD FACC⁩ ⁦Minnow Walsh, MD, MACC⁩ ⁦James Januzzi Jr MD⁩ ⁦Anu Lala-Trindade⁩

Brett James Januzzi Jr MD

#Jacci made her first air journey home to New England in the care of our Editors and got to meet our fearless leader Harlan Krumholz Mitsuaki Sawano, MD

New kid on the block in #HCM ?

At #ACC24 , I sat down with Martin Maron, MD to discuss ninerafaxstat and the IMPROVE-HCM trial in nonobstructive HCM.

Check out the clip below:
hcplive.com/view/ninerafax…

#Cardiomyopathy Ahmad Masri James Januzzi Jr MD Dermot Phelan theodoreabraham

We’re part of the #BridgeToTheFuture . Are you? #ACC24 American College of Cardiology #ACCGivesBack

Go to ACC.org/annualfund or text ACC75 to 41444 and join the movement!

This is beautiful....trainees and all should study how easily this summary flows...amazing James Januzzi Jr MD

Live from 75th Convocation! American College of Cardiology #ACC2024

Talk about dedication! Incoming #JACC Deputy Editor Extraordinaire Dr. Erica Spatz adopted a puppy/Journal mascot at #ACC24 , named Jacqueline Peaches - #Jacci ! JACC Journals couldn’t be more excited!

Selective aldose reductase inhibition with AT-001 no different than placebo in improving peak VO2 in diabetic cardiomyopathy. Dr. Januzzi and I discuss the results of the ARISE-HF study.

Meet the amazing new Editorial Board of JACC: Case Reports!

Reporting live from the puppy petting booth #ACC24

ICYMI: Dr. James Januzzi Jr MD is spotlighting his groundbreaking #JACC late-breaking clinical trial, the ARISE-HF trial.

Dive into the full paper here for all the details: bit.ly/49xfMcq

#ACC24 #Diabetes #HeartFailure #ARISE #Cardiology #ACCessPoints

#ARISE -HF : Study on #Aldose  Reductase Inhibitor (AT-001) for #DbCM

📍A total of 691
📍Mean age 67.5 yr
📍Equal gender participation 👍

📌Placebo group saw a significant decline in peak Vo2, while high-dose AT-001 showed stability (difference of 0.30, P=0.19).

📌Notable…

'We speculate that a more representative population of individuals with less tightly controlled glucose might effectively reveal AT-001 to improve cardiovascular outcomes,” says Dr. @JJHeart_doc on the ARISE-HF trial. #ACC24

Last day of #ACC24 & start fresh w/ the result of #ARISEHF by James Januzzi Jr MD:

▶️691 px w/ #DiabeticCardiomyopathy (50% 👩), ⬇️pVO2 <75%, receiving #AT001 🆚 placebo for 15 mo

▶️ pVO2 in placebo ⬇️, but statistically not significant

🔗: jacc.org/doi/10.1016/j.…

Congratulations 👏🏻

This is probably one of the most monumental events in my life...I got to present Dr. Richard Allen Williams with an award from ACC as not only a member but also a member of ABC. I know it was over in a flash, but these pics will always remain in my heart
.

#ACC24 #SimPub by Alberto Foà in JACC Journals

Fascinating observation from #PARAGONHF — pts w LVEF above 60% were at *higher* risk of hypotension & *lower* likelihood of benefit w #ARNI sacubitril/valsartan

Reinforces current guidance for pt selection

jacc.org/doi/10.1016/j.…

Now online JACC Journals, primary results of the #ARISE -HF clinical trial of aldose reductase inhibitor treatment with AT-001 for patients with #DiabeticCardiomyopathy

#ACC24 #ACC2024 American College of Cardiology

secure-web.cisco.com/14PRHiPQwkwSfl…